Dyne Therapeutics (DYN) is stepping into a pivotal week, with investors laser focused on tomorrow’s topline readout from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial for DYNE-251 ...

The weekly The Bold and the Beautiful must-watch moments for December 22—26 tease that Hope faces a conundrum when she’s forced to fire Deke and when Thomas asks for alone time with her. Plus, Carter ...

The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares. Just after market close on Monday, Dyne announced that it has launched an underwritten public ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...

Dyne Therapeutics (NASDAQ: DYN) was hardly having a bad case of the Mondays. Shares of the clinical-stage biotech were racing more than 9% higher in mid-session action, as the company delivered rather ...

Enemy Intel Inflicting enough damage will pressure him. When his HP is reduced, he will fuse with scrap metal to perform powerful attacks. During this time, he will be difficult to pressure. However, ...

Help could be coming for the Green Bay Packers defensive front over the final four games of 2025. According to coach Matt LaFleur, third-year defensive end Lukas Van Ness will return to practice on ...

Tottenham Hotspur have been warned by a legendary figure that Micky van de Ven has no intention of signing an extension to his deal in north London, with sources revealing how the news will likely ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...